-
Press Release
2021/06/17
Abnova COVID-19 Antigen Rapid Test Nasal Cavity Sampling Advantage Speeds Up Home Use IRB Submission and Clinical Study
-
Press Release
2021/03/23
Abnova File for Universal COVID-19 Self-Amplifying mRNA Vaccine Patent and Establish GMP Manufacturing Partnership
-
Press Release
2021/03/12
Abnova COVID-19 Humanized Antibody Effective Against Both UK (B.1.1.7) and South Africa (B.1.351) Variants
-
Press Release
2021/02/23
Abnova Introduces Neutralizing Antibody Test for COVID-19, UK, and South Africa Variants for Post-Vaccine Era
-
Press Release
2021/01/14
Abnova Adds Point-of-Care (POC) Utility to its COVID-19 Viral Antigen Rapid Test for US EUA Submission
-
Press Release
2021/01/11
Abnova Re-Focus and Develop First COVID-19 Humanized Antibody for Inhaled Therapeutic and Nasal Spray Prophylactic Uses
-
Press Release
2020/12/08
Abnova Completes COVID-19 Viral Antigen Rapid Test US Clinical Study, Sensitivity 100% and Specificity 96%.
-
Press Release
2020/11/04
Abnova Initiates COVID-19 Viral Antigen Rapid Testing in Japan and US
-
Press Release
2020/10/26
Abnova & Leadgene Develop High Sensitivity COVID-19 Viral Antigen Rapid Tests
-
Press Release
2020/10/14
Abnova & Leadgene Completes COVID-19 Antibody Humanization and Validation for its 7F7 Best-in-Class Antibody Lead Candidate